ライフサイエンスコーパス: parasitemia

1 use no immediate symptoms (ie, "asymptomatic parasitemia").

2 VSG antibody response, which rapidly reduced parasitemia.

3 sure does not completely prevent blood-stage parasitemia.

4 ined as P. vivax clearance without recurrent parasitemia.

5 ontributed to the IL-4-dependent decrease in parasitemia.

6 ssociated with increasing age and concurrent parasitemia.

7 mic effect that exposure to bites has on the parasitemia.

8 ith antimicrobial treatment and clearance of parasitemia.

9 with asymptomatic carriage and undetectable parasitemia.

10 osis, including clearance of Babesia microti parasitemia.

11 and all correlated with age, independent of parasitemia.

12 resulting in impaired control of persistent parasitemia.

13 trine exposure is a determinant of recurrent parasitemia.

14 , sex, Ebola viremia, and Plasmodium species parasitemia.

15 hamsters and the subsequent examination for parasitemia.

16 -infected individuals, correlated with lower parasitemia.

17 ype I IFN response in the early clearance of parasitemia.

18 hanced Th1 immune response that reduced peak parasitemia.

19 nical syndromes despite low peripheral blood parasitemia.

20 repeat CHMI at 59 weeks, and none developed parasitemia.

21 hanced Th1 immune response that reduced peak parasitemia.

22 mmunized and -challenged mice rendered lower parasitemia.

23 rug treatment, correlating with clearance of parasitemia.

24 during malaria and associated with elevated parasitemia.

25 changes in the levels of both thioethers and parasitemia.

26 nly misdiagnosed in patients with incidental parasitemia.

27 travelers, O-iRBCs peaked at 107.7% initial parasitemia.

28 ligand PfRh5 was the best predictor of donor parasitemia.

29 No association was identified with parasitemia.

30 long-term alterations induced by blood-stage parasitemia.

31 sure does not completely prevent blood-stage parasitemia.

32 (IgG) and Fc receptor activation to control parasitemia.

33 sitemia; and healthy adults (n = 23) without parasitemia.

34 iciency; all patients had confirmed P. vivax parasitemia.

35 a 30-d period of infection with undetectable parasitemia.

36 during infection compared to mice with mild parasitemia.

37 nd schizogony both affect initial changes in parasitemia.

38 p to 1 year for the detection of reappearing parasitemia.

39 Compound 22a reduced parasitemia 10(9) fold in trypanosome-infected mice; it

40 /2), having a PC1/2 of >=5 hours, and having parasitemia 3 days after treatment.

41 ds of having a PC1/2 of >=5 hours and having parasitemia 3 days after treatment.

42 at risk, P<0.001), as was the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine grou

43 which incorporates improved measurements of parasitemia, a novel gametocyte dynamics model and model

44 n the incidence of malaria and prevalence of parasitemia, a proportion of the population remained par

45 UIS3 can induce a consistent delay in patent parasitemia across mouse strains and against chimeric pa

46 End points were time to parasitemia, adverse events and immune responses.

47 Endpoints were time to parasitemia, adverse events, and immune responses.

48 tion, we found that concurrent P. falciparum parasitemia also increases the likelihood of the first a

49 en the respective prevalence of asymptomatic parasitemia among children was 81 and 15 percent by micr

50 t alter risks of clinical malaria or malaria parasitemia among school children and that school-based

51 I resulted in 29/34 (85%) volunteers with Pf parasitemia and 15/34 (44%) with malaria (parasitemia an

52 ent risk factors for severe malaria included parasitemia and angiopoietin-2 in knowlesi malaria, and

53 causes malaria, are critical for control of parasitemia and associated immunopathology.

54 cute stage of infection is marked by intense parasitemia and cardiac tissue parasitism, resulting in

55 mice developed fulminating and uncontrolled parasitemia and died significantly earlier (13 +/- 1 d)

56 ax malaria patients with different levels of parasitemia and during the acute and convalescent phases

57 Microscopic parasitemia and expression of the immunoregulatory marke

58 ission and nadir hemoglobin, controlling for parasitemia and fever duration.

59 ren who differed in their ability to control parasitemia and fever following Pf infection.

60 a and symptomatic cardiomyopathy (SYL), mild parasitemia and high tissue tropism (COL), to no pathoge

61 sing proportion of interval assessments with parasitemia and higher parasite densities were independe

62 l death and their relationship to control of parasitemia and host mortality.

63 like E3 ubiquitin ligase (Pyheul) influences parasitemia and host mortality.

64 prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure." METH

65 The prevalence of malaria parasitemia and incidence of adverse events were similar

66 Immunity that controls parasitemia and inflammation during Plasmodium falciparu

67 GCR correlates positively with parasitemia and is negatively influenced by fever, not h

68 and good correlation of antigen levels with parasitemia and its clearance after drug treatment.

69 EA-1-vaccinated dams had significantly lower parasitemia and longer survival following a P. berghei c

70 a MEK1/2 inhibitor approach controls malaria parasitemia and mitigates pathogenic effects on host org

71 +) cells, IFN-gamma, and NO, on the level of parasitemia and parasite clearance during acute babesios

72 ium chabaudi offers the best protection from parasitemia and pathology in reinfection cases, correlat

73 within total NK cells correlated with lower parasitemia and resistance to malaria.

74 ehavior in a murine model, ranging from high parasitemia and symptomatic cardiomyopathy (SYL), mild p

75 Pf parasitemia and 15/34 (44%) with malaria (parasitemia and symptoms).

76 RBP2-P1 antibodies are associated with lower parasitemia and tend to be higher in asymptomatic carrie

77 otegerin level correlated with the levels of parasitemia and the malaria clinical score.

78 e virus and examine the role of the virus in parasitemia and the pathogenesis of leishmaniasis.

79 Finally, parasitemia and tissue parasite burden in mice were high

80 eins in bronchoalveolar lavage fluid, higher parasitemia and tissue parasite burden, and increased nu

81 s-sectional surveys to identify asymptomatic parasitemia and used active surveillance over 11325 chil

82 f 24 hours, a direct correlation between the parasitemia and volatile levels was revealed.

83 Differences in characteristics of parasitemias and drug resistance polymorphisms by CPT st

84 pared with Cd36(-/-) mice, WT mice had lower parasitemias and were resistant to death.

85 nate and adaptive immune responses, controls parasitemia, and blocks pathogenesis.

86 tection from subsequent clinical malaria and parasitemia, and fewer blood-stage specific CD4(+) T cel

87 ction (PCR) were used to detect asymptomatic parasitemia, and hotspots were detected using the spatia

88 r, these tests often miss cases of low-level parasitemia, and PfHRP-II tests can give false-negative

89 to monitor the development and clearance of parasitemia, and plasma artefenomel concentration.

90 nsity and positivity correlated closely with parasitemia, and population gametocyte prevalence decrea

91 t is observed following recrudescent asexual parasitemia, and these gametocytes are again refractory

92 ic P falciparum (n = 19) or P vivax (n = 21) parasitemia; and healthy adults (n = 23) without parasit

93 The frequency, density, and timing of parasitemia are all important risk factors for placental

94 Population-level survey data on parasitemia are limited and traditionally exclude adults

95 Using Pf-iRBCs at 0.1% parasitemia as a testing sample, the microfluidic deform

96 artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase cha

97 38 (78%) children had a >/= 99% reduction in parasitemia at 24 h compared to 263/331 (79%) receiving

98 ortion of children with >/= 99% reduction in parasitemia at 24 h from admission values, measured by m

99 /333 (74%) children had >/= 99% reduction in parasitemia at 24 h; hence, non-inferiority of this regi

100 Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome

101 The mean prevalence of malaria parasitemia at baseline was 8.9% (95% CI 5.1%-15.7%; 52

102 ART duration, 4.5 years), 5% had detectable parasitemia at baseline.

103 The proportion of patients with parasitemia at Day 3 was 24.0% (40/167; 95% CI 17.7-31.2

104 h a 70% reduction of harboring P. falciparum parasitemia at the heterozygous state (odds ratio [OR] f

105 infected erythrocytes, which likely maintain parasitemias below clinical and immunological radar.

106 Log-rank test was used to compare time-to-parasitemia between interventions.

107 t-line antimalarial drugs that rapidly clear parasitemia, but recrudescences of the infection frequen

108 IRS significantly reduced the prevalence of parasitemia, but the prevalence remained high (pre-IRS t

109 6/6 and 5/6 volunteers developed parasitemia, but time to first parasitemia was significa

110 6/6 and 5/6 volunteers developed parasitemia, but time to first parasitemia was significa

111 lass of antimalarial drugs that can suppress parasitemia by inhibiting a host target that cannot be m

112 and eighty-two inhabitants were screened for parasitemia by nested polymerase chain reaction (nPCR).

113 All 22 CHMIs in controls resulted in parasitemia by qPCR.

114 et of cytokines/chemokines and the levels of parasitemia by quantitative PCR in the circulation of ne

115 All 22 CHMIs in controls resulted in parasitemia by quantitative polymerase chain reaction.

116 d flow, leads to inflammation, and increases parasitemia by reducing spleen-mediated clearance of the

117 The ability to easily and rapidly determine parasitemia by THG offers potential not only for the eas

118 noculation and were followed for 35 days for parasitemia by thick blood smear (TBS) and quantitative

119 noculation and were followed for 35 days for parasitemia by thick blood smear (TBS) and quantitative

120 ablish that a marked reduction in B. microti parasitemia can be reliably achieved with peak blood lev

121 T. cruzi infection, as evidenced by reduced parasitemia, cardiac tissue inflammation, and parasite b

122 ymptomatic infections, with no difference in parasitemia characteristics.

123 IL-4 treatment significantly reduced parasitemia, CM pathology, and mortality.

124 thromycin had approximately half the odds of parasitemia compared to those treated with placebo (odds

125 ol parasite replication, resulted in similar parasitemia compared with control mice.

126 -87%) vaccinated volunteers remained without parasitemia compared with none of six nonvaccinated cont

127 3%) of six (95% CI, 36-99%) remained without parasitemia compared with none of six nonvaccinated cont

128 en associated with a lower risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ

129 undetectable viral load had a lower risk of parasitemia, compared with HIV-uninfected individuals (a

130 d a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >20

131 ure of circulating parasites, accounting for parasitemia control and host survival.

132 N-gamma in mediating splenic cell apoptosis, parasitemia control, and host lethality and thus may pro

133 Plasmodium knowlesi parasitemia correlated with age (Spearman's correlation

134 False-negative RDT results with high parasitemia could be due to non-falciparum infection or

135 Cd47(-/-) mice displayed significantly lower parasitemia, decreased endothelial activation, and enhan

136 f 9 (77.8%) in the sero-high group developed parasitemia detected by TBS in the first 28 days (P = .1

137 f 9 (77.8%) in the sero-high group developed parasitemia detected by TBS in the first 28 days (p = 0.

138 None of the 34 women without parasitemia detected during pregnancy had evidence of pl

139 Microscopic parasitemia developed in 22 individuals, and 21 in vitro

140 The prevalence and density of malaria parasitemia did not differ by treatment group at any of

141 prim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of

142 lls in the lamina propria and mice with high parasitemia display specific metabolomic profiles in the

143 rited traits, and find evidence that malaria parasitemia does contribute to the pathogenesis of retin

144 patic activin B was also upregulated at peak parasitemia during infection with Plasmodium chabaudi Co

145 lationships between longitudinal measures of parasitemia during pregnancy and placental malaria.

146 sure associations between characteristics of parasitemia during pregnancy and the risk of placental m

147 rious impact of submicroscopic P. falciparum parasitemia during pregnancy on multiple pregnancy outco

148 tion of mice with recombinant SGM1.7 reduced parasitemia early in the infection.

149 Primary end points were risks of recurrent parasitemia, either unadjusted or adjusted to distinguis

150 1 (55%) vaccinated subjects remained without parasitemia following CHMI 21 weeks after immunization.

151 dies had a reduced probability of developing parasitemia following homologous challenge (p<0.05); v)

152 ured by the rate of exponential clearance of parasitemia following treatment.

153 man malaria infection and were monitored for parasitemia for 21 days.

154 man malaria infection and were monitored for parasitemia for 21 days.

155 ral treatment of P. falciparum episodes with parasitemia >=2% without severe signs at presentation wa

156 individuals and malaria patients presenting parasitemias >0.3%.

157 ad and age; those with the highest levels of parasitemia had a survival rate of 83%.

158 Plasmodium parasitemia had no impact on EVD outcomes.

159 visceral leishmaniasis elimination campaigns.Parasitemia has been considered the main determinant of

160 ars, cases of severe and high-level P. vivax parasitemia have been reported, challenging the assumpti

161 We assessed the kinetics of parasitemia in 112 volunteers infected with blood-stage

162 del of HAT, the compound was unable to clear parasitemia in a CNS model of the disease.

163 potent in vitro, showed full suppression of parasitemia in a mouse model of acute infection, and eli

164 from both clinical malaria and high-density parasitemia in a prospective longitudinal study of child

165 e-stimulated monocytes in vitro and reducing parasitemia in a rodent model of experimental cerebral m

166 ontrast, NETs were inversely associated with parasitemia in adults with asymptomatic P falciparum inf

167 . cruzi mouse model, where 6a and 6b reduced parasitemia in animals >99% following intraperitoneal ad

168 ion and is able to detect very low levels of parasitemia in both blood cultures as well as animal mod

169 ger children (P = .0001), and the decline in parasitemia in children aged 1.5-4 years often started 6

170 ne gene expression, and Ag clearance, so low parasitemia in comparison with haplotypes other than GTA

171 are conflicting on the role of asymptomatic parasitemia in determining the risk of developing febril

172 ransmission intensity, age, and asymptomatic parasitemia in determining the risk of developing febril

173 n in a PK study and significant reduction of parasitemia in four out of the six mice.

174 ction, but it increased disease severity and parasitemia in mice infected with Plasmodium chabaudi AS

175 ast, 11beta-HSD1 deficiency rather decreased parasitemia in mice infected with the reticulocyte-restr

176 atients with cerebral malaria and those with parasitemia in other organs.

177 ods were compared for sensitive detection of parasitemia in P. falciparum cultures.

178 s) with bound platelets during the ascending parasitemia in Plasmodium chabaudi- and Plasmodium bergh

179 rsons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to

180 t possibly enabling exposed women to control parasitemia in the face of pregnancy-induced Th2 polariz

181 The prevalence of malaria parasitemia in the study population was 77.8% (1447/1860

182 ociated with a reduced prevalence of malaria parasitemia in this trial, suggesting one possible mecha

183 oelii infection through delayed clearance of parasitemia in wild type C57BL/6jRj (B6) compared with T

184 mL(-1) in spiked samples and for 0.006-1.5% parasitemias in Plasmodium-infected cultured red blood c

185 generalist strains would lead to higher peak parasitemias in vivo compared to specialist strains with

186 rculation that is not captured by peripheral parasitemia, in particular in patients with complicated

187 The parasitemia incidence was 42.0 cases per 100 person-year

188 t T cells expanded after asexual blood-stage parasitemia induced by CHMI.

189 rates of nondetection of infection among low-parasitemia infections, which increase in frequency with

190 AhR KO mice displayed significantly reduced parasitemia, inflammation, and fibrosis of the myocardiu

191 Models were adjusted for age, sex, parasitemia, inflammation, and study site.

192 Plasmodium species parasitemia is associated with an increase in the probab

193 Asymptomatic parasitemia is common even in areas of low seasonal mala

194 malaria-endemic areas, Plasmodium falciparum parasitemia is common in apparently healthy children and

195 Asymptomatic parasitemia is modified by transmission intensity and ag

196 Subpatent and asymptomatic multispecies parasitemia is relatively common in North Sumatera, so P

197 idence of malaria, but its impact on malaria parasitemia is unclear.

198 ptomatic, submicroscopic Plasmodium knowlesi parasitemia is unknown.

199 Early changes in parasitemia level (ie, 0-6 hours after admission) were d

200 ether subjects experienced rises or falls in parasitemia level after treatment.

201 obtained after exposure to bites, as did the parasitemia level and the number of monocytes in the cir

202 oncentration at baseline (P = <.001), higher parasitemia level at baseline (P = .02), and thalassemia

203 alarials were unable to prevent rises in the parasitemia level in the first 12 hours.

204 acting but not slow-acting drugs reduced the parasitemia level independent of when treatment was admi

205 udes the highly variable lag phase, when the parasitemia level may increase, remain constant, or decr

206 n the parasite growth cycle, and whether the parasitemia level rose or fell in the first 12 or 24 hou

207 The parasitemia level was measured by quantitative polymeras

208 nalysis showed that the plasma PfHRP2 level, parasitemia level, total bilirubin level, and RCD at a s

209 icity for the PLS-DA was found to be 98% for parasitemia levels >0.5%, but a rather low sensitivity o

210 deficient for galectin-3 have elevated blood parasitemia levels and impaired cytokine production duri

211 We found that B. microti reaches high parasitemia levels during the first week of infection in

212 on status correctly in 93.4% of samples with parasitemia levels higher than 5 parasites/uL when compa

213 , 7, and 10 induced a remarkable decrease in parasitemia levels in acute phase and the parasitemia re

214 bioencapsulating the artemisinin reduced the parasitemia levels in challenged mice in comparison with

215 t they are more prone to be parasitized with parasitemia levels that are more successfully detected b

216 On day 3 or 4 postinfection, when parasitemia levels typically exceeded 10%, mice were tre

217 cant differences in platelet counts or blood parasitemia levels were observed between VWF(-/-) and WT

218 tion for subjects 1 and 2 respectively (peak parasitemia levels, 174 182 and 50 291 parasites/mL, res

219 e immuno-polymerase chain reaction (PCR), to parasitemia limits of 0.02 parasite/microL and 0.78 para

220 Most infections (55.6%) had parasitemias <= 10 parasites/uL.

221 with <=1 comorbidity), had a lower degree of parasitemia (<10%), and were less likely to have end-org

222 c cell deformability sensor for quantitative parasitemia measurement and stage determination for Plas

223 T. cruzi (Y strain) and determined levels of parasitemia, myocardial inflammation and fibrosis, expre

224 children in the community with asymptomatic parasitemia (n=33).

225 od, to determine the risk of Plasmodium spp. parasitemia (n=8390) and Plasmodium falciparum HRP-2 (Pf

226 The improved control of parasitemia observed in the absence of CXCL10-mediated t

227 Parasitemia occurs frequently during pregnancy, but rout

228 Of 143 children with a geometric mean parasitemia of 116,294/uL (95% CI: 95,574-141,505), 91 (

229 romising compound (13) showed a reduction in parasitemia of 96% when dosed at 30 mg/kg orally once a

230 aria outcome was the community prevalence of parasitemia on thick blood smear, assessed in a random s

231 Women with parasitemia only detected before the third trimester sti

232 ed for triggers such as high-density asexual parasitemia or drug treatment.

233 T. cruzi-specific B cells failed to control parasitemia or prevent death.

234 cruzi, even before they developed detectable parasitemia or seroconversion.

235 , whereas all placebo participants developed parasitemia (P = .0005).

236 oquine arm subjects displayed delayed patent parasitemia (P = .01) but not sterile protection, while

237 oquine arm subjects displayed delayed patent parasitemia (p=0.01) but not sterile protection, while 3

238 , DMMB-GAG was significantly associated with parasitemia [partial correlation coefficient (P(corr)) =

239 Malaria parasitemia persists in humans at levels that optimize t

240 controlled HIV infection had a lower risk of parasitemia, presumably reflecting access to HIV care.

241 resulted in progressive increases in malaria parasitemia prevalence and burden.

242 low for label-free, rapid and cost-effective parasitemia quantification and stage determination for m

243 More than 30,000 RBCs can be analyzed for parasitemia quantification in under 1min with a throughp

244 glucose and urea analytes along with malaria parasitemia quantification using one spectrum obtained f

245 in parasitemia levels in acute phase and the parasitemia reactivation following immunosuppression, an

246 Rates, quantity, and timing of parasitemia rebound following CTX remain undefined.

247 wed significant in vivo efficacy with 73% of parasitemia reduction in a mouse model.

248 re able to reliably detect very low level of parasitemia (representing early stage of infection, ~0.0

249 g vitamin A were less likely to present with parasitemia (RR=0.46, 95% CI=0.39-0.54) and antigenemia

250 usting for age, sex, nutritional status, and parasitemia, SA children with BWF had higher risk of rea

251 nfection and developed a 9.3-fold lower peak parasitemia than their wild-type (WT) counterparts.

252 s for malaria but fail to detect low-density parasitemias that are important for maintaining malaria

253 r T cell responses are required for limiting parasitemia, these responses need to be switched off by

254 hould target the prevention of all levels of parasitemia throughout pregnancy.

255 t of HEIs (n = 471) were tested for malarial parasitemia using dried blood spots from 12, 24, and 36

256 ate by CellaVision was 100% (23/23) when the parasitemia was >/=2.5%.

257 The detection rate for <0.1% parasitemia was 63% (15/24).

258 The community prevalence of parasitemia was 83.8% (95% confidence interval [CI], 82.

259 Plasmodium falciparum parasitemia was assessed using microscopy and ultrasensi

260 Having asymptomatic malaria parasitemia was associated with a 40% increase in respir

261 ransmission intensity settings, asymptomatic parasitemia was associated with a reduced risk of febril

262 the lower transmission setting, asymptomatic parasitemia was associated with an increased risk of feb

263 sma piperaquine concentration at the time of parasitemia was associated with increasing pfmdr1 86Y pr

264 Parasitemia was detected 7 days after inoculation, and p

265 re likely to survive when Plasmodium species parasitemia was detected, even after controlling for Ebo

266 -treated bed nets, the prevalence of malaria parasitemia was high across all ages, peaking in school-

267 Parasitemia was identified by active surveillance every

268 Plasmodium falciparum parasitemia was less frequent than in non-BWF controls,

269 nally, the risk associated with asymptomatic parasitemia was limited to the first 90 days of follow-u

270 In the prespecified primary analysis, parasitemia was lower in the azithromycin-treated group

271 The risk of recurrent parasitemia was lower with DHA-PQ as compared to AL at a

272 Parasitemia was monitored by quantitative real-time poly

273 Parasitemia was not affected by ET-1 treatment.

274 ce during the acute phase of infection, when parasitemia was rapidly rising.

275 Parasitemia was reduced by over 90% in P. berghei infect

276 ers developed parasitemia, but time to first parasitemia was significantly longer than controls in th

277 ers developed parasitemia, but time to first parasitemia was significantly longer than controls in th

278 The median time to parasitemia was significantly shorter in the sero-low gr

279 The median time to parasitemia was significantly shorter in the sero-low gr

280 P chabaudi primary and secondary parasitemia was similar in mice depleted of platelets by

281 Parasitemia was successfully managed with preemptive tre

282 ing a weighted proportion, and predictors of parasitemia were identified using a multivariate Poisson

283 Risks of recurrent parasitemia were lower with AS/AQ at all 3 sites (overal

284 gative CM that would be prevented if malaria parasitemia were to be eliminated is estimated to be 0.9

285 Peripheral parasitemias were highest in those with uncomplicated ma

286 ticipants who received tafenoquine developed parasitemia, whereas all placebo participants developed

287 in T. cruzi-infected infants correlated with parasitemia, whereas the plasma levels of IL-17A, IL-17F

288 he disease pathology is a consequence of the parasitemia which develops through cyclical replication

289 f) proliferation and strongly decreased peak parasitemia, which is consistent with improved Teff func

290 K cells with anti-NK1.1 mAb led to increased parasitemia, which was accompanied by significant reduct

291 hloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs such as prim

292 hloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs, such as pri

293 egies depend on identifying individuals with parasitemia, who may be asymptomatic but retain the abil

294 s with low (LPVM) and moderately-high (MPVM) parasitemia with healthy community controls.

295 nd 49, effecting 98% and 99.93% reduction in parasitemia with mean survival days of 12 and 14, respec

296 tion of (1) CPT and (2) asymptomatic malaria parasitemia with respiratory and diarrheal morbidity in

297 All volunteers developed blood-stage parasitemia, with no impact of the vaccine on PMR.

298 Primary outcomes were risks of recurrent parasitemia within 28 days, with or without adjustment t

299 sites, with a >90% reduction in the level of parasitemia within just 4 days.

300 hat asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P